A healthy lifestyle and survival among women with ovarian cancer
Jessy Hansen(Monash University), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Michael Friedländer(Prince of Wales Hospital), Anna DeFazio(The University of Sydney), Christina M. Nagle(The University of Queensland), Torukiri I Ibiebele(QIMR Berghofer Medical Research Institute), Andreas Obermair(Royal Brisbane and Women's Hospital), Peter Grant(The University of Melbourne)
Cited by 43
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k